e-therapeutics to present at Shares Investor Evening
Oxford, UK, 15 May 2020 – e-therapeutics plc (AIM: ETX.L, “e-therapeutics” or “the Company”) will be presenting at the Shares Investor Evening – Webinar sponsored by AJ Bell on Tuesday 19th May 2020. The webinar will start at 18:00 BST and investors can register to attend here: https://www.sharesmagazine.co.uk/events/event/shares-investor-evening–webinar-190520
Ali Mortazavi, Executive Chairman of e-therapeutics, will be presenting an overview of the Company and will be available to take questions during the event.
For more information, please contact:
Ali Mortazavi, Executive Chairman
Laura Roca-Alonso, Chief Business Officer
Tel: +44 (0)1993 883 125
Numis Securities Limited
Freddie Barnfield/Duncan Monteith (Nominated Adviser)
James Black (Corporate Broking)
Tel: +44 (0) 207 260 1000
Simon Conway/Stephanie Cuthbert
Tel: +44 (0) 203 727 1000
Email: [email protected]
e-therapeutics is an Oxford, UK-based company with a unique and powerful computer-based approach to drug discovery, founded on our industry-leading expertise in network biology.
We have created two proprietary, unique and productive technologies. The first is Network-driven Drug Discovery (“NDD”), which is based on cutting-edge network science, statistics, machine learning and artificial intelligence. NDD allows the more efficient discovery of new and better drugs and has been validated in multiple and diverse areas of biology.
The second is Genome Associated Interaction Networks (“GAINs”). GAINs is a revolutionary and entirely novel approach to functional genomics, based on the same validated network biology and analytics expertise that underpins our NDD technologies. GAINs analyses human genetic data to provide a deep and valuable understanding of the mechanisms that cause disease. GAINs has the potential to uncover unrecognised disease processes and pathways and can enable the discovery of novel drugs, diagnostics and biomarkers in a way not previously possible from population genomics data, such as genome-wide association studies (“GWAS”).
We have deployed our highly productive drug discovery platform technologies to develop our own IP-protected, pre-clinical drug discovery programmes that are available to partners seeking to acquire or in-license novel and differentiated assets.
We have partnerships with Novo Nordisk in Type-2 diabetes and a US-based, top 5 pharmaceutical company in neurodegeneration. We are working on different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.